Modulateurs du récepteur adrénergique bêta 3 utile dans le traitement ou la prévention de troubles associés à ceux-ci
Cette invention concerne certains composés de formule (ia) et leurs compositions pharmaceutiques qui modulent l'activité du récepteur adrénergique bêta 3. Des composés de la présente invention et leurs compositions pharmaceutiques ciblent des procédés utiles dans le traitement d'un trouble...
Gespeichert in:
| Hauptverfasser: | , , , , |
|---|---|
| Format: | Patent |
| Sprache: | fre |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | |
| container_volume | |
| creator | ULLMAN, Brett TRAN, Thuy-Anh Anthony C. Blackburn Maiko Nagura DO, Quyen-Quyen |
| description | Cette invention concerne certains composés de formule (ia) et leurs compositions pharmaceutiques qui modulent l'activité du récepteur adrénergique bêta 3. Des composés de la présente invention et leurs compositions pharmaceutiques ciblent des procédés utiles dans le traitement d'un trouble médié par le récepteur adrénergique bêta 3, tel que l'insuffisance cardiaque, l'activité cardiaque dans l'insuffisance cardiaque, la mortalité, la récidive d'infarctus et/ou l'hospitalisation en relation avec l'insuffis
The present invention relates to compounds of Formula (Ia) and pharmaceutical compositions thereof that modulate the activity of the beta-3 adrenergic receptor. Compounds of the present invention and pharmaceutical compositions thereof are directed to methods useful in the treatment of a beta-3 adrenergic receptor-mediated disorder, such as, heart failure; cardiac performance in heart failure; mortality, reinfarction, and/or hospitalization in connection with heart failure; acute heart failure; acute decompensated heart failure; congestive heart failure; severe congestive heart failure; organ damage associated with heart failure (e.g., kidney damage or failure, heart valve problems, heart rhythm problems, and/or liver damage); heart failure due to left ventricular dysfunction; heart failure with normal ejection fraction; cardiovascular mortality following myocardial infarction; cardiovascular mortality in patients with left ventricular failure or left ventricular dysfunction; left ventricular failure; left ventricular dysfunction; class II heart failure using the New York Heart Association (NYHA) classification system; class III heart failure using the New York Heart Association (NYHA) classification system; class IV heart failure using the New York Heart Association (NYHA) classification system; LVEF |
| format | Patent |
| fullrecord | <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_MA44037B1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>MA44037B1</sourcerecordid><originalsourceid>FETCH-epo_espacenet_MA44037B13</originalsourceid><addsrcrecordid>eNqFi0EKwjAQRbtxIeoVZC5QUFpwraK46c59mSajBGJSMxkRvIzbeo1czBTcu3o8_vvT4tV4LRYjSWDQAiENivpRAXUWR-Fq7kLQpU9EqECisQQaHUNmDGgi3chF8AIWoc-fR1bjHehx99JZYkBmr0waGNIbFMmzVGZeTC5omRY_zorl8XDen0rqfUvcoyJHsW22db2qNrt19Tf4AipTSeA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>Modulateurs du récepteur adrénergique bêta 3 utile dans le traitement ou la prévention de troubles associés à ceux-ci</title><source>esp@cenet</source><creator>ULLMAN, Brett ; TRAN, Thuy-Anh ; Anthony C. Blackburn ; Maiko Nagura ; DO, Quyen-Quyen</creator><creatorcontrib>ULLMAN, Brett ; TRAN, Thuy-Anh ; Anthony C. Blackburn ; Maiko Nagura ; DO, Quyen-Quyen</creatorcontrib><description>Cette invention concerne certains composés de formule (ia) et leurs compositions pharmaceutiques qui modulent l'activité du récepteur adrénergique bêta 3. Des composés de la présente invention et leurs compositions pharmaceutiques ciblent des procédés utiles dans le traitement d'un trouble médié par le récepteur adrénergique bêta 3, tel que l'insuffisance cardiaque, l'activité cardiaque dans l'insuffisance cardiaque, la mortalité, la récidive d'infarctus et/ou l'hospitalisation en relation avec l'insuffis
The present invention relates to compounds of Formula (Ia) and pharmaceutical compositions thereof that modulate the activity of the beta-3 adrenergic receptor. Compounds of the present invention and pharmaceutical compositions thereof are directed to methods useful in the treatment of a beta-3 adrenergic receptor-mediated disorder, such as, heart failure; cardiac performance in heart failure; mortality, reinfarction, and/or hospitalization in connection with heart failure; acute heart failure; acute decompensated heart failure; congestive heart failure; severe congestive heart failure; organ damage associated with heart failure (e.g., kidney damage or failure, heart valve problems, heart rhythm problems, and/or liver damage); heart failure due to left ventricular dysfunction; heart failure with normal ejection fraction; cardiovascular mortality following myocardial infarction; cardiovascular mortality in patients with left ventricular failure or left ventricular dysfunction; left ventricular failure; left ventricular dysfunction; class II heart failure using the New York Heart Association (NYHA) classification system; class III heart failure using the New York Heart Association (NYHA) classification system; class IV heart failure using the New York Heart Association (NYHA) classification system; LVEF<40% by radionuclide ventriculography; LVEF≤35% by echocardiography or ventricular contrast angiography; and conditions related thereto.</description><language>fre</language><subject>CHEMISTRY ; HETEROCYCLIC COMPOUNDS ; HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; METALLURGY ; ORGANIC CHEMISTRY ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><creationdate>2020</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20200331&DB=EPODOC&CC=MA&NR=44037B1$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,777,882,25545,76296</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20200331&DB=EPODOC&CC=MA&NR=44037B1$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>ULLMAN, Brett</creatorcontrib><creatorcontrib>TRAN, Thuy-Anh</creatorcontrib><creatorcontrib>Anthony C. Blackburn</creatorcontrib><creatorcontrib>Maiko Nagura</creatorcontrib><creatorcontrib>DO, Quyen-Quyen</creatorcontrib><title>Modulateurs du récepteur adrénergique bêta 3 utile dans le traitement ou la prévention de troubles associés à ceux-ci</title><description>Cette invention concerne certains composés de formule (ia) et leurs compositions pharmaceutiques qui modulent l'activité du récepteur adrénergique bêta 3. Des composés de la présente invention et leurs compositions pharmaceutiques ciblent des procédés utiles dans le traitement d'un trouble médié par le récepteur adrénergique bêta 3, tel que l'insuffisance cardiaque, l'activité cardiaque dans l'insuffisance cardiaque, la mortalité, la récidive d'infarctus et/ou l'hospitalisation en relation avec l'insuffis
The present invention relates to compounds of Formula (Ia) and pharmaceutical compositions thereof that modulate the activity of the beta-3 adrenergic receptor. Compounds of the present invention and pharmaceutical compositions thereof are directed to methods useful in the treatment of a beta-3 adrenergic receptor-mediated disorder, such as, heart failure; cardiac performance in heart failure; mortality, reinfarction, and/or hospitalization in connection with heart failure; acute heart failure; acute decompensated heart failure; congestive heart failure; severe congestive heart failure; organ damage associated with heart failure (e.g., kidney damage or failure, heart valve problems, heart rhythm problems, and/or liver damage); heart failure due to left ventricular dysfunction; heart failure with normal ejection fraction; cardiovascular mortality following myocardial infarction; cardiovascular mortality in patients with left ventricular failure or left ventricular dysfunction; left ventricular failure; left ventricular dysfunction; class II heart failure using the New York Heart Association (NYHA) classification system; class III heart failure using the New York Heart Association (NYHA) classification system; class IV heart failure using the New York Heart Association (NYHA) classification system; LVEF<40% by radionuclide ventriculography; LVEF≤35% by echocardiography or ventricular contrast angiography; and conditions related thereto.</description><subject>CHEMISTRY</subject><subject>HETEROCYCLIC COMPOUNDS</subject><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>METALLURGY</subject><subject>ORGANIC CHEMISTRY</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2020</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNqFi0EKwjAQRbtxIeoVZC5QUFpwraK46c59mSajBGJSMxkRvIzbeo1czBTcu3o8_vvT4tV4LRYjSWDQAiENivpRAXUWR-Fq7kLQpU9EqECisQQaHUNmDGgi3chF8AIWoc-fR1bjHehx99JZYkBmr0waGNIbFMmzVGZeTC5omRY_zorl8XDen0rqfUvcoyJHsW22db2qNrt19Tf4AipTSeA</recordid><startdate>20200331</startdate><enddate>20200331</enddate><creator>ULLMAN, Brett</creator><creator>TRAN, Thuy-Anh</creator><creator>Anthony C. Blackburn</creator><creator>Maiko Nagura</creator><creator>DO, Quyen-Quyen</creator><scope>EVB</scope></search><sort><creationdate>20200331</creationdate><title>Modulateurs du récepteur adrénergique bêta 3 utile dans le traitement ou la prévention de troubles associés à ceux-ci</title><author>ULLMAN, Brett ; TRAN, Thuy-Anh ; Anthony C. Blackburn ; Maiko Nagura ; DO, Quyen-Quyen</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_MA44037B13</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>fre</language><creationdate>2020</creationdate><topic>CHEMISTRY</topic><topic>HETEROCYCLIC COMPOUNDS</topic><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>METALLURGY</topic><topic>ORGANIC CHEMISTRY</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><toplevel>online_resources</toplevel><creatorcontrib>ULLMAN, Brett</creatorcontrib><creatorcontrib>TRAN, Thuy-Anh</creatorcontrib><creatorcontrib>Anthony C. Blackburn</creatorcontrib><creatorcontrib>Maiko Nagura</creatorcontrib><creatorcontrib>DO, Quyen-Quyen</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>ULLMAN, Brett</au><au>TRAN, Thuy-Anh</au><au>Anthony C. Blackburn</au><au>Maiko Nagura</au><au>DO, Quyen-Quyen</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>Modulateurs du récepteur adrénergique bêta 3 utile dans le traitement ou la prévention de troubles associés à ceux-ci</title><date>2020-03-31</date><risdate>2020</risdate><abstract>Cette invention concerne certains composés de formule (ia) et leurs compositions pharmaceutiques qui modulent l'activité du récepteur adrénergique bêta 3. Des composés de la présente invention et leurs compositions pharmaceutiques ciblent des procédés utiles dans le traitement d'un trouble médié par le récepteur adrénergique bêta 3, tel que l'insuffisance cardiaque, l'activité cardiaque dans l'insuffisance cardiaque, la mortalité, la récidive d'infarctus et/ou l'hospitalisation en relation avec l'insuffis
The present invention relates to compounds of Formula (Ia) and pharmaceutical compositions thereof that modulate the activity of the beta-3 adrenergic receptor. Compounds of the present invention and pharmaceutical compositions thereof are directed to methods useful in the treatment of a beta-3 adrenergic receptor-mediated disorder, such as, heart failure; cardiac performance in heart failure; mortality, reinfarction, and/or hospitalization in connection with heart failure; acute heart failure; acute decompensated heart failure; congestive heart failure; severe congestive heart failure; organ damage associated with heart failure (e.g., kidney damage or failure, heart valve problems, heart rhythm problems, and/or liver damage); heart failure due to left ventricular dysfunction; heart failure with normal ejection fraction; cardiovascular mortality following myocardial infarction; cardiovascular mortality in patients with left ventricular failure or left ventricular dysfunction; left ventricular failure; left ventricular dysfunction; class II heart failure using the New York Heart Association (NYHA) classification system; class III heart failure using the New York Heart Association (NYHA) classification system; class IV heart failure using the New York Heart Association (NYHA) classification system; LVEF<40% by radionuclide ventriculography; LVEF≤35% by echocardiography or ventricular contrast angiography; and conditions related thereto.</abstract><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | |
| ispartof | |
| issn | |
| language | fre |
| recordid | cdi_epo_espacenet_MA44037B1 |
| source | esp@cenet |
| subjects | CHEMISTRY HETEROCYCLIC COMPOUNDS HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY ORGANIC CHEMISTRY PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS |
| title | Modulateurs du récepteur adrénergique bêta 3 utile dans le traitement ou la prévention de troubles associés à ceux-ci |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-18T02%3A23%3A31IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=ULLMAN,%20Brett&rft.date=2020-03-31&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EMA44037B1%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |